Ursodeoxycholic acid for primary biliary cirrhosis (Q24202184)

5

0 references

Goran Bjelakovic

4

0 references

Goran Poropat

object named as

Goran Poropat

2

0 references

author name string

Jelena S Rudic

1

0 references

Miodrag N Krstic

Cochrane Database of Systematic Reviews

3

0 references

publication date

12 December 2012

0 references

published in

0 references

cites work

Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Characterisation of patients with a complete biochemical response to ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodeoxycholic acid therapy for primary biliary cirrhosis. A 10-year British single-centre population-based audit of efficacy and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Serial Quantitative Liver Function Tests in Patients with Primary Biliary Cirrhosis: A Prospective Long-Term Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

A perfect correlate does not a surrogate make

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Prognosis in primary biliary cirrhosis: model for decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Bias in clinical intervention research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Hepatic transport of bile salts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Agreement between reported use of interventions for liver diseases and research evidence in Cochrane systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

The natural history of PBC: has it changed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Patients and patience: the pitfalls of primary biliary cirrhosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Primary biliary cirrhosis: a 2010 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

The epidemiology of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodeoxycholic acid in the treatment of liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Serum bilirubin: a prognostic factor in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Mechanism of hepatoprotective action of bile salts in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

How should meta-regression analyses be undertaken and interpreted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Ursodeoxycholic acid for primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD000551.PUB3

Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.

21 January 2018

1 reference

12 December 2020

The natural history of abdominal pain associated with primary biliary cirrhosis

1 reference

12 December 2020

American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis

1 reference

12 December 2020

A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid

1 reference

12 December 2020

A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis

1 reference

12 December 2020

Prolonged treatment with ursodeoxycholic acid for primary biliary cirrhosis

1 reference

12 December 2020

Pharmacology of ursodeoxycholic acid, an enterohepatic drug.

1 reference

12 December 2020

Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy

1 reference

12 December 2020

[Eosinophilia in primary biliary cirrhosis: regression under therapy with ursodeoxycholic acid]

1 reference

12 December 2020

Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation

1 reference

12 December 2020

Ursodeoxycholic acid for primary biliary cirrhosis

1 reference

12 December 2020

Ursodeoxycholic acid for chronic liver diseases

1 reference

12 December 2020

Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis

1 reference

12 December 2020

Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines

1 reference

12 December 2020

Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis

1 reference

12 December 2020

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

12 December 2020

Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease

1 reference

12 December 2020

Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC

1 reference

12 December 2020

[Taurodeoxycholic acid in the treatment of primary biliary cirrhosis. A controlled study in comparison to ursodeoxycholic acid]

1 reference

12 December 2020

Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

12 December 2020

Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study

1 reference

12 December 2020

Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?

1 reference

12 December 2020

A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group

1 reference

12 December 2020

Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.

1 reference

12 December 2020

Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine

1 reference

12 December 2020

Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group

1 reference

12 December 2020

Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

12 December 2020

Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration

1 reference

12 December 2020

Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis

1 reference

12 December 2020

Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis

1 reference

12 December 2020

Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression

1 reference

12 December 2020

How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study.

1 reference

12 December 2020

Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis

1 reference

12 December 2020

Primary biliary cirrhosis

1 reference

12 December 2020

Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis

1 reference

12 December 2020

Eosinophilia in primary biliary cirrhosis

1 reference

12 December 2020

Primary biliary cirrhosis

1 reference

12 December 2020

The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

12 December 2020

[Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: results of a controlled study]

1 reference

12 December 2020

[Ursodeoxycholic acid in the treatment of primary biliary cirrhosis]

1 reference

12 December 2020

Effect of different doses of ursodeoxycholic acid in chronic liver disease

1 reference

12 December 2020

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

1 reference

12 December 2020

Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study

1 reference

12 December 2020

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

12 December 2020

Significance of subtype pattern of antimitochondrial antibodies in primary biliary cirrhosis for prognostic parameters and response to ursodeoxycholic acid

1 reference

12 December 2020

Ursodeoxycholic Acid Delays the Onset of Esophageal Varices in Primary Biliary Cirrhosis

1 reference

12 December 2020

Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy

1 reference

12 December 2020

Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid

1 reference

12 December 2020

Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis

1 reference

12 December 2020

Biochemical and histological changes after more than four years of treatment of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

12 December 2020

Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment

1 reference

12 December 2020

Primary biliary cirrhosis. 1950.

1 reference

12 December 2020

Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis

1 reference

12 December 2020

Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis

1 reference

12 December 2020

Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis

1 reference

12 December 2020

Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis

1 reference

12 December 2020

Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response

1 reference

12 December 2020

Xanthomatous biliary cirrhosis; a clinical syndrome

1 reference

12 December 2020

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver

1 reference

12 December 2020

Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.

1 reference

12 December 2020

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

12 December 2020

Fatigue in primary biliary cirrhosis

1 reference

12 December 2020

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up

1 reference

12 December 2020

Results of long-term ursodiol treatment for patients with primary biliary cirrhosis

1 reference

12 December 2020

Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis

1 reference

12 December 2020

[Ursodeoxycholic acid in primary biliary cirrhosis. 2: Prospective long-term study of 21 patients]

1 reference

12 December 2020

Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy

1 reference

12 December 2020

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

1 reference

12 December 2020

A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

12 December 2020

Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study

1 reference

12 December 2020